|Day Low/High||4.52 / 4.86|
|52 Wk Low/High||2.57 / 10.00|
Here are Monday's top research calls, including upgrades for American Eagle, Mattel and Tesaro, and new coverage of Netflix.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CVRR, TTNP, WMS Downgrades: DAR Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Titan Pharmaceuticals Inc , where a total of 4,278 contracts have traded so far, representing approximately 427,800 underlying shares. That amounts to about 262.5% of TTNP's average daily trading volume over the past month of 163,000 shares.
Results Demonstrate the Superiority of Probuphine for Abstinence from Opioids for Patients over Six Months
Patients and Providers Have a New Option to Combat Opioid Dependence
These stocks trading for less than $10 a share look ready to break out and trade higher from current levels.
Titan Pharmaceuticals (TTNP) stock is climbing after the FDA's Psychopharmacologic Drugs Advisory Committee voted in favor of approving the company's treatment for opioid addiction.
These under-$10 biotech stocks are within range of triggering major breakout trades.
Titan and its partner will resubmit Probuphine for FDA approval later this year.
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Titan Pharmaceuticals,...
FDA find much at fault with Titan's implantable therapy for opioid dependence.
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
Join TheStreet's Adam Feuerstein for his live blog covering the FDA panel reviewing Titan's treatment for opioid addiction.
Titan Pharmaceuticals is the next big thing in biotech, Adam Feuerstein, Sr. Columnist for TheStreet, tells Gregg Greenberg
Contestants in TheStreet's FDA Drug Approval Contest think well of Sarepta, Navidea and Biogen, less so about Arena, Aveo and Delcath.